Diabetes Mellitus, Insulin-Dependent Clinical Trial
Official title:
Safety and Efficacy of Mesenchymal Stem Cells in Newly-diagnosed Type 1 Diabetic Patients
Type 1 diabetes mellitus results from the autoimmune destruction of the insulin producing pancreatic β-cells. The autoimmune response begins months or even years before the presentation of hyperglycemic symptoms. Previous studies with other autoimmune diseases or acute inflammatory diseases testing the effect of the infusion of mesenchymal stem cells showed promising results in regulating immune system and promoting some degree of disease control. The aim of our study is to determine the safety and efficacy of intravenous infusions of mesenchymal stem cells in newly diagnosed type 1 diabetic patients.
Patients from 12 to 35 years old with type I diabetes mellitus proved by anti-pancreatic beta cell antibodies and recently diagnosed (less than 6 weeks) will be included in this study. First, bone marrow derived adult mesenchymal stem cells are collected from a first degree relative and cultured. After that, the patient receive 4 intravenous infusions 1 week apart followed by 4 infusion 4 months apart. ;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00035750 -
Risk Factors for Atherogenesis in Type 1 Diabetes
|
N/A | |
| Completed |
NCT00005754 -
Coronary Artery Calcification in Type 1 Diabetes
|
N/A | |
| Completed |
NCT00005474 -
Markers and Mechanisms of Macrovascular Disease in IDDM
|
N/A | |
| Completed |
NCT01216618 -
Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies
|
Phase 3 | |
| Completed |
NCT01236365 -
Statins in Children With Type 1 Diabetes and Hypercholesterolemia
|
Phase 3 | |
| Completed |
NCT00071409 -
Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes
|
Phase 2 | |
| Completed |
NCT00069537 -
Continuous Glucose Monitors for Children With Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT05168657 -
Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth
|
N/A | |
| Withdrawn |
NCT00297635 -
Telemetric Glucose Data Acquisition During Initiation of Insulin Pump Therapy
|
Phase 2 | |
| Completed |
NCT00184821 -
Ischemic Injury and Ischemic Preconditioning in Diabetes
|
N/A | |
| Completed |
NCT00073255 -
Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
|
Phase 1 | |
| Completed |
NCT00690066 -
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
|
Phase 2 | |
| Active, not recruiting |
NCT04078308 -
Mesenchymal Stem Cells Transplantation in Newly Diagnosed Type-1 Diabetes Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00069628 -
Randomized Clinical Trial to Assess the Effectiveness of the GlucoWatch Biographer
|
Phase 4 | |
| Completed |
NCT00044395 -
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
|
Phase 3 | |
| Completed |
NCT00044408 -
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
|
Phase 3 | |
| Completed |
NCT00069615 -
Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children
|
Phase 4 | |
| Completed |
NCT00005539 -
Wisconsin Epidemiological Study of Cardiovascular Disease in Type 1 Diabetes
|
N/A | |
| Completed |
NCT04689685 -
The RADAR Study - Wearable-Based Dysglycemia Detection and Warning in Diabetes
|
||
| Completed |
NCT00357890 -
Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
|
N/A |